Arkansas
Requires Coverage of Comprehensive Biomarker Testing
Only for some plans
Highlighted Disparity
Cancer data are not available for Arkansas for 2021 and 2022
Lung Cancer Rates
New Cases:
- The rate of new lung cancer cases in Arkansas is 68.2 and significantly higher than the national rate of 52.8.
- Arkansas ranks 47th among all states, placing it in the below average tier.
- The change in the rate of new cases over the last five years is not available for Arkansas.
- In 2022, the most recent year of data available for this report, the COVID-19 pandemic continued to disrupt access to medical care, including delays and reductions in cancer diagnoses and screening. This led to a decline in incidence rates for most cancers, including lung cancer, and should not be interpreted as a reduction in the underlying cancer burden.
5-Year Survival Rate:
- The percent of people alive five years after being diagnosed with lung cancer (the survival rate) is 29.7% nationally.
- Arkansas is one of the 12 states for which survival data is not available, as they do not track cases after diagnosis.
Early Diagnosis:
- The early diagnosis rate is not available for Arkansas due to missing data for 2021 and 2022.
Lung Cancer Treatment
Surgical Treatment:
- Nationally, 20.7% of cases undergo surgery as part of the first course of treatment.
- Data on surgery as part of the first course of treatment is not available for Arkansas due to no data for 2021 and 2022.
Biomarker Coverage:
- Arkansas required some insurance plans to cover comprehensive biomarker testing, including for lung cancer, as of August 2025.
No Treatment:
- Nationally, 21.0% of cases received no treatment.
- Data on lack of treatment is not available for Arkansas for 2021 and 2022.
Screening
Screening for High Risk:
- In Arkansas, 16.6% of those at high risk were screened, which was not significantly different than the national rate of 18.2%.
- It ranks 33rd among all states, placing it in the average tier.
Prevention
Tobacco Use:
- The 2023 smoking rate in Arkansas is 15.0% and significantly higher than the national rate of 11.4%.
- It ranks 41st among all states, placing it in the below average tier.
Radon:
- In Arkansas, 20.1% of radon test results were at or above the action level recommended by EPA.
- It ranks 20th among all states, placing it in the average tier.
Racial & Ethnic Disparities
Black individuals:
- The rate of new lung cancer cases is 65.7 per 100,000 population among Black individuals in Arkansas, significantly higher than the rate of 54.2 among Black individuals nationally, and not significantly different than the rate of 69.7 among white individuals in Arkansas.
- Survival rates by race and ethnicity are not available for Arkansas at this time. Nationally, the five-year survival rate among Black individuals is 27.1%, 9% lower than among white Americans.
- Lung cancer rates are not available for Arkansas due to the impact of COVID-19 on cancer surveillance in 2021.
Latino individuals:
- The rate of new lung cancer cases is 41.0 per 100,000 population among Latino individuals in Arkansas, significantly higher than the rate of 27.9 among Latino individuals nationally, and significantly lower than the rate of 69.7 among white individuals in Arkansas.
- State-level survival rates are not available for Latino individuals at this time. Nationally, the five-year survival rate among Latino individuals is 22.7%, not significantly different than the rate of 25.0% among white individuals.
- Lung cancer rates are not available for Arkansas due to the impact of COVID-19 on cancer surveillance in 2021.
Asian Americans or Pacific Islanders:
- The rate of new lung cancer cases is 34.6 per 100,000 population among Asian or Pacific Islanders individuals in Arkansas, not significantly different than the rate of 32.5 among Asian or Pacific Islanders individuals nationally, and significantly lower than the rate of 69.7 among white individuals in Arkansas.
- State-level survival rates are not available for Asian or Pacific Islander individuals at this time. Nationally, the five-year survival rate among Asian or Pacific Islander individuals is 28.6% and significantly higher than the rate of 25.0% among white individuals.
- Lung cancer rates are not available for Arkansas due to the impact of COVID-19 on cancer surveillance in 2021.
Indigenous Peoples:
- The rate of new lung cancer cases is 60.4 per 100,000 population among Indigenous peoples (American Indians/Alaska Natives) in Arkansas, significantly higher than the rate of 39.8 among Indigenous Peoples nationally, and not significantly different than the rate of 69.7 among white individuals in Arkansas.
- State-level survival rates are not available for Indigenous Peoples at this time. Nationally, the five-year survival rate among Indigenous Peoples is 22.3% and not significantly different than the rate of 25.0% among white individuals.
- Lung cancer rates are not available for Arkansas due to the impact of COVID-19 on cancer surveillance in 2021.
Summary
Early diagnosis data is not available for Arkansas. When this rate increases, we can anticipate that the surgery rate would increase, as surgery is often the recommended treatment for those diagnosed at an earlier stage. In addition, when cases are found earlier, we would expect the five-year survival rate to increase.
Arkansas required some insurance plans to cover comprehensive biomarker testing, which can help determine what treatment options would be best for individuals with lung cancer and other diseases.
Page last updated: October 1, 2025